Revenue from operations increased 11.18% YoY to Rs 66.75 crore during the quarter ended 30 September 2024. Profit before tax (PBT) jumped 24.36% YoY to Rs 13.63 crore in Q2 FY25. In Q2 FY25, EBITDA stood at Rs 24.51 crore, registering the growth of 14.6% as compared with Rs 21.39 crore posted in corresponding quarter last year. EBITDA margin stood at 36.7% in Q2 FY25 as against 35.6% in Q2 FY24. As of September 2024, the company's consolidated net cash stood at Rs 49.83 crore compared to Rs 46.38 crore at the end of FY24 Ritu Mittal, joint managing director & CEO said, 'Our focus on operational efficiency, revenue growth, has translated into robust results, reflecting our ability to navigate the business landscape effectively. Over the years, we have been able to drive consistent improvement in revenue per patient and EBITDA per patient which stood at Rs 2,099 and Rs 761, respectively in H1 FY25. We believe we are on a solid footing to win, given the changing customer preference towards organized diagnostic chains from standalone centres. West Bengal continues to be the prominent market for our company, with 47 out of the total 51 centers located in the state. We remain committed in our endeavor to drive further growth from the Eastern and North-Eastern markets in India. We believe the strong results position us well to drive sustainable top-line and margin growth. As a publicly listed entity, we remain committed to enhancing shareholder value by executing on our welldefined strategies to expand into our core markets and also exploring inorganic growth opportunities. In conclusion, I would like to thank all stakeholders, past and present, and hope for continued support as we strive to reach scale newer summits.' The shares of Suraksha Diagnostic entered into the stock market on 6 December 2024. The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price of Rs 441. Suraksha Diagnostic is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The scrip declined 1.98% to Rs 404.45 on the BSE.Powered by Capital Market - Live

Net profit of Suraksha Diagnostic rose 22.95% to Rs 10.34 crore in the quarter ended September 2024 as against Rs 8.41 crore during the previous quarter ended September 2023. Sales rose 11.16% to Rs 66.75 crore in the quarter ended September 2024 as against Rs 60.05 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales66.7560.05 11 OPM %34.7634.69 - PBDT22.3818.91 18 PBT13.6310.97 24 NP10.348.41 23 Powered by Capital Market - Live

Suraksha Diagnostic will hold a meeting of the Board of Directors of the Company on 20 December 2024.Powered by Capital Market - Live

The scrip was listed at Rs 437, exhibiting a discount of 0.91% to the issue price. So far, the stock has hit a high of 449 and a low of 426.65. On the BSE, over 2.32 lakh shares of the company were traded in the counter so far. The initial public offer (IPO) of Suraksha Diagnostics was subscribed 1.27 times. The issue opened for bidding on Friday (29 November 2024), and it closed on Tuesday (03 December 2024). The price band of the IPO was fixed between Rs 420 and 441 per share. The IPO comprised an offer for sale of 1,91,89,330 equity shares, aggregating up to Rs 846.25 crore. The promoters and promoter group hold an aggregate of 3,18,02,034 equity shares, aggregating to 61.07% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 48.78%. Ahead of the IPO, Suraksha Diagnostics on Thursday, 28 November 2024, raised Rs 253.87 crore from anchor investors. The board allotted 57.56 crore shares at Rs 441 each to 16 anchor investors. Suraksha Diagnostics offers a one-stop integrated solution for pathology, radiology testing, and medical consultancy services, providing a comprehensive range of over 2,300 tests across various specialties and disciplines, as of June 30, 2024. The diagnostic test menu includes (a) 788 routine pathology tests, covering basic biochemistry and hematology to 664 specialized tests like advanced biochemistry, histopathology, and molecular pathology, and (b) 766 basic/intermediate radiology tests, including x-rays, ultrasonography (USG), and CT scans, along with 119 advanced radiology tests like MRI scans and specialized CT scans. Radiology equipment consists of 24 CT and 13 MRI machines. The firm reported a consolidated net profit of Rs 7.94 crore and sales of Rs 60.73 crore for the three months ended on 30 June 2024.Powered by Capital Market - Live

The equity shares of Suraksha Diagnostic (Scrip Code: 544293) are listed effective 06 December 2024 and admitted to dealings on the Exchange in the list of ''B'' Group Securities. Powered by Capital Market - Live